Condition: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) · Sponsor: Amgen
The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Recruiting |
| Midwestern Regional Medical Center dba City of Hope Chicago | Zion, Illinois, United States | Recruiting |
| Community Health Network MD Anderson Cancer Center - North | Indianapolis, Indiana, United States | Recruiting |
| New England Cancer Specialists | Westbrook, Maine, United States | Recruiting |
| Tennessee Oncology PLLC | Nashville, Tennessee, United States | Recruiting |
| Next Oncology - Dallas | Irving, Texas, United States | Recruiting |
| Calvary Mater Newcastle Hospital | Waratah, New South Wales, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Universite Catholique de Louvain Cliniques Universitaires Saint Luc | Brussels, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07403721